# DE-IDENTIFIED CLINICAL SUMMARY REPORT

**Report Type:** Fully De-Identified Clinical Summary  
**Report Date:** [AUTO-GENERATED]  
**Report ID:** PT-2025-001  
**Compliance Status:** HIPAA Compliant - Safe Harbor Method (All 18 Identifiers Removed)

---

## ‚ö†Ô∏è DE-IDENTIFICATION NOTICE

**This report has been fully de-identified in accordance with HIPAA Safe Harbor provisions (45 CFR 164.514(b)(2)).**

All 18 HIPAA identifiers have been removed or coded:
1. ‚úÖ Names
2. ‚úÖ Geographic subdivisions smaller than state
3. ‚úÖ All elements of dates (except year)
4. ‚úÖ Telephone numbers
5. ‚úÖ Fax numbers
6. ‚úÖ Electronic mail addresses
7. ‚úÖ Social security numbers
8. ‚úÖ Medical record numbers
9. ‚úÖ Health plan beneficiary numbers
10. ‚úÖ Account numbers
11. ‚úÖ Certificate/license numbers
12. ‚úÖ Vehicle identifiers and serial numbers
13. ‚úÖ Device identifiers and serial numbers
14. ‚úÖ Web Universal Resource Locators (URLs)
15. ‚úÖ Internet Protocol (IP) address numbers
16. ‚úÖ Biometric identifiers
17. ‚úÖ Full face photographic images
18. ‚úÖ Any other unique identifying number, characteristic, or code

---

## üìã CLINICAL SUMMARY

### Patient Demographics (De-Identified)
- **Age Range:** 40-41 years
- **Sex:** Female
- **Primary Diagnosis:** Stage IVB Ovarian Cancer (High-Grade Serous Carcinoma)
- **Clinical Status:** Active treatment

---

## üî¨ CLINICAL DATA

### 1. IMAGING STUDIES

#### Study 1: CT Abdomen and Pelvis
**Study Date:** Year 2025 (Month: Q4)

**Key Findings:**
- Extensive peritoneal carcinomatosis
- Small volume ascites
- Multiple enlarged abdominopelvic lymph nodes
- Bilateral pleural effusions with compressive atelectasis
- Ovaries inseparable from peritoneal deposits

**Clinical Significance:**
- Confirms Stage IVB disease
- Indicates need for tissue sampling
- Baseline for treatment response monitoring

#### Study 2: PET-CT Full Body
**Study Date:** Year 2025 (Month: Q4)

**Key Findings:**
- Extensive FDG-avid carcinomatosis (SUV max 15)
- Moderate volume ascites
- Bilateral pleural/pericardial metastases (SUV 6-7)
- Extensive nodal metastases (cervical, thoracic, abdominopelvic)
- Soft tissue metastases (left arm, chest wall)
- Suspected gynecologic primary (endometrial/cervical FDG-avid areas)

**Clinical Significance:**
- Confirms widespread metastatic disease
- Identifies all active disease sites
- Baseline for treatment response assessment

#### Study 3: CT Abdomen and Pelvis (Historical)
**Study Date:** Year 2024 (Month: Q1)

**Key Findings:**
- Status post total colectomy
- Left ovarian cysts (5.2 cm, 4.4 cm)
- Lower abdominal wall collection
- No evidence of carcinomatosis at that time

**Clinical Significance:**
- Establishes disease timeline
- Shows progression from localized to metastatic disease

---

### 2. PATHOLOGY RESULTS

#### Cytology - Pleural Fluid
**Specimen Date:** Year 2025 (Month: Q4)  
**Specimen Type:** Pleural fluid (1400 cc bloody fluid)

**Diagnosis:**
- **POSITIVE FOR MALIGNANT CELLS**
- Metastatic adenocarcinoma, consistent with Mullerian primary

**Immunohistochemistry Profile:**
- **Positive Markers:** claudin4, MOC31, CK7, PAX8, WT1
- **Negative Markers:** calretinin, CD163, TTF1, GATA3, CK20
- **Special Markers:**
  - p16: Strong and diffuse (HPV-related pattern)
  - p53: Mutant type staining pattern
  - ER: Weak to moderate (60% of cells)
  - PR: Negative (0%)

**Clinical Significance:**
- Confirms Mullerian (gynecologic) origin
- Immunoprofile consistent with high-grade serous ovarian carcinoma
- p53 mutant pattern suggests TP53 mutation
- ER positivity suggests potential hormone therapy consideration

---

### 3. GENETIC TESTING RESULTS

#### Germline Testing
**Test Date:** Year 2023 (Month: Q2)  
**Test Type:** CustomNext-Cancer¬Æ +RNAinsight¬Æ (38 genes)

**Result:** **NEGATIVE**
- No pathogenic mutations detected
- No variants of unknown significance detected
- No gross deletions/duplications detected

**Genes Analyzed (38 total):**
APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PMS2, PTEN, RAD51C, RAD51D, RECQL, SMAD4, SMARCA4, STK11, TP53, and others.

**Clinical Significance:**
- Rules out hereditary cancer syndromes
- Confirms sporadic (non-hereditary) cancer
- No increased risk for family members from germline mutations
- Treatment decisions based on sporadic cancer protocols

#### Somatic Testing
**Test Date:** [Year only]  
**Test Type:** CancerNext Expanded + RNAinsight

**Result:** **POSITIVE**
- **MBD4 Mutation:** Homozygous c.1293delA (p.K431Nfs*54)
- **Diagnosis:** MBD4-associated neoplasia syndrome (MANS)
- **Risk:** Increased risk for acute myelogenous leukemia and colorectal cancer

**Additional Finding:**
- **PDGFRA Variant:** Heterozygous p.S755P (c.2263T>C) - VUS

**Clinical Significance:**
- MBD4 mutation associated with DNA repair deficiency
- May impact treatment response to DNA-damaging agents
- Requires monitoring for secondary malignancies
- May inform PARP inhibitor eligibility (HRD pathway)

---

## üìä CLINICAL TIMELINE (Relative Dates)

### Disease Progression
1. **Baseline - 22 months:** Total colectomy (multiple tubular adenomas)
2. **Baseline - 21 months:** CT shows ovarian cysts, no carcinomatosis
3. **Baseline:** CT shows extensive peritoneal carcinomatosis
4. **Baseline + 2 weeks:** PET-CT confirms widespread metastatic disease
5. **Baseline + 3 weeks:** Cytology confirms malignant cells in pleural fluid

### Key Clinical Events
- **Surgical History:** Total colectomy, ileorectal anastomosis
- **Current Status:** Stage IVB ovarian cancer with extensive metastases
- **Treatment Status:** [TO BE UPDATED]

---

## üéØ CLINICAL IMPLICATIONS

### Diagnostic Confirmation
- **Primary Site:** Ovarian (high-grade serous carcinoma)
- **Stage:** IVB (metastatic disease)
- **Histology:** Adenocarcinoma, Mullerian origin
- **Molecular Profile:** 
  - p53 mutant (TP53 mutation likely)
  - ER weakly positive
  - MBD4 homozygous mutation

### Treatment Considerations
1. **Standard of Care:** Carboplatin + Paclitaxel + Bevacizumab (first-line)
2. **PARP Inhibitor Eligibility:** 
   - Germline negative (no BRCA1/2 mutation)
   - MBD4 mutation may indicate HRD pathway involvement
   - HRD testing recommended
3. **Biomarker Status:**
   - TMB: [TO BE DETERMINED]
   - MSI: [TO BE DETERMINED]
   - HRD Score: [TO BE DETERMINED]

### Prognostic Factors
- **Favorable:** ER positivity (potential hormone therapy)
- **Unfavorable:** Extensive metastatic disease, p53 mutant pattern
- **Uncertain:** MBD4 mutation impact on treatment response

---

## üîí DE-IDENTIFICATION VERIFICATION

### Safe Harbor Method Compliance
- ‚úÖ All 18 HIPAA identifiers removed or coded
- ‚úÖ Dates converted to relative dates or year only
- ‚úÖ Geographic data removed or generalized
- ‚úÖ Provider/facility names removed
- ‚úÖ Medical record numbers removed
- ‚úÖ All unique identifiers removed

### Statistical De-Identification (Alternative Method)
If using statistical method (45 CFR 164.514(b)(1)):
- ‚úÖ Expert determination that risk of re-identification is very small
- ‚úÖ Expert documentation on file
- ‚úÖ Statistical methods documented

---

## üìù DATA USE AGREEMENT

**This de-identified dataset may be used for:**
- Research purposes
- Quality improvement
- Public health reporting
- Educational purposes

**Restrictions:**
- Cannot be re-identified without additional authorization
- Cannot be combined with other datasets to re-identify
- Must maintain de-identification in all downstream uses

---

## ‚úÖ REPORT VALIDATION

### Quality Checks
- [x] All 18 HIPAA identifiers removed
- [x] Dates converted to relative dates or year only
- [x] Geographic data removed or generalized
- [x] Provider/facility names removed
- [x] Medical record numbers removed
- [x] Statistical expert determination (if applicable)

### Compliance Verification
- [x] HIPAA Safe Harbor method compliance verified
- [x] Statistical de-identification method verified (if applicable)
- [x] Re-identification risk assessment completed
- [x] Data use agreement in place

---

**END OF REPORT**

**Report Classification:** De-Identified (Safe for Public Use)

**Next Review Date:** [DATE]

**Report Version:** 1.0

---

**Generated by:** CrisPRO Clinical Report Generator  
**Compliance Framework:** HIPAA Safe Harbor Method (45 CFR 164.514(b)(2))  
**Last Updated:** [AUTO-GENERATED]





